title: HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma.
abstract: BACKGROUND
  Histone deacetylase 6 (HDAC6) is correlated with poor/better survival from cancers. This study was designed to investigate the correlation between HDAC6 expression and renal cell carcinoma (RCC) patients.
  
  
  METHODS
  A total of 45 fresh RCC samples and 132 paraffin embedded tissues as well as their corresponding adjacent non-tumor tissues were collected by surgical excision. The qRT-PCR, western blotting analysis and immunohistochemically analysis were performed to detect the expression of HDAC6. Kaplan-Meier curves analysis and Cox proportional hazards model were used to analysis patients survivals as well as to adjust stratification factors.
  
  
  RESULTS
  The experimental results demonstrated that HDAC6 mRNA expression level was significantly upregulated in RCC tissues compared with adjacent non-tumor tissues, and its expression was correlated with histologic grade and poor overall survival of RCC patients. RCC patients with higher HDAC6 expression showed relative poor survival. Moreover, both HDAC6 expression and histologic grade were correlated with RCC prognosis, and high HDAC6 expression was an independent, poor prognostic factor in patient with RCC.
  
  
  CONCLUSIONS
  These analyses showed that high HDAC6 expression was an independent, poor prognostic factor in patients with RCC, and HDAC6 could serve as a biomarker of RCCs prognostic and an indicator for RCC progression.
authors.affiliation: Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.|Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
authors.forename: Zijian
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shangdong, China.|Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
authors.forename: Yanwei
authors.initials: Y
authors.lastname: Cao
authors.affiliation: Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
authors.forename: Weiming
authors.initials: W
authors.lastname: Zhao
authors.affiliation: Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shangdong, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Guo
authors.affiliation: Department of Reproductive Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
authors.forename: Wanpeng
authors.initials: W
authors.lastname: Liu
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D002292:Carcinoma, Renal Cell / Q000378:metabolism / Q000556:secondary* / Q000601:surgery; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D000073864:Histone Deacetylase 6 / Q000378:metabolism*; D006801:Humans; D007680:Kidney Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D011379:Prognosis; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; C433811:HDAC6 protein, human; D000073864:Histone Deacetylase 6
keywords: Histone deacetylase 6; overall survival; prognosis; renal cell carcinoma